Amanta Healthcare Ltd

Amanta Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. Despite achieving record net sales and a strong operating profit to interest ratio, the company’s operating profit margin contracted significantly, prompting a downgrade in its Mojo Grade from Hold to Sell.

Amanta Healthcare Limited, a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹493.00 crores, reported a mixed performance for Q4 FY26 (January-March 2026), with net profit rising to ₹5.53 crores from ₹4.63 crores in the previous quarter, marking a sequential growth of 19.44%. However, the quarter revealed concerning margin compression, with operating profit margins declining to 19.42% from 20.62% in Q3 FY26, whilst the stock surged 7.15% to ₹133.30 following the results announcement.

Amanta Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 17 May 2026, providing investors with the most up-to-date perspective on the company’s performance and outlook.

Amanta Healthcare Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and financial performance. The upgrade, effective from 5 May 2026, is driven by a combination of enhanced technical trends, robust quarterly financial results, attractive valuation metrics, and increased institutional participation, despite some lingering concerns over long-term fundamentals and debt servicing capacity.

Amanta Healthcare Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a strong day change of 6.73% and a current price of ₹140.30, the stock’s technical indicators present a nuanced picture, with bullish signals from MACD and Bollinger Bands contrasting with bearish RSI readings. This article analyses these technical parameters in detail, placing the stock’s performance in the context of broader market trends and its sector.

Amanta Healthcare Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest day gain of 0.44%, the stock’s recent performance and technical signals suggest a cautious outlook amid mixed momentum cues.

Amanta Healthcare Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 April 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 27 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 15 Apr 2026. This change reflects a combination of improved technical indicators, positive quarterly financial results, and a more attractive valuation profile, signalling cautious optimism among investors despite some lingering fundamental challenges.

Amanta Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 7 April 2026. This change reflects a nuanced assessment across four critical parameters: quality, valuation, financial trend, and technicals. Despite some encouraging quarterly financial results, the overall outlook has been tempered by weak long-term fundamentals and a shift in technical momentum.

Amanta Healthcare Ltd has seen its investment rating upgraded from Sell to Hold as of 2 April 2026, driven primarily by a marked improvement in technical indicators and encouraging quarterly financial results. The micro-cap pharmaceutical company’s recent performance reflects a cautiously optimistic outlook amid mixed long-term fundamentals.

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 April 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

Amanta Healthcare Ltd’s share price declined to a fresh 52-week low of Rs 93.1 on 23 March 2026, marking a significant milestone in the stock’s recent performance amid broader market weakness and sectoral pressures.

Despite a broader market rally, Amanta Healthcare Ltd has plunged to a fresh 52-week low of Rs 93.1 on 23 Mar 2026, marking a significant divergence from sector and index trends.

Amanta Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 22 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.